Cargando…

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?

Introduction: In Europe and beyond, the rising costs of healthcare and limited healthcare resources have resulted in the implementation of health technology assessment (HTA) to inform health policy and reimbursement decision-making. European legislation has provided a harmonized route for the regula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allen, Nicola, Liberti, Lawrence, Walker, Stuart R., Salek, Sam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491965/ https://www.ncbi.nlm.nih.gov/pubmed/28713265 http://dx.doi.org/10.3389/fphar.2017.00384

Ejemplares similares

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Strategy for communicating benefit-risk decisions: a comparison of regulatory agencies' publicly available documents
por: Leong Wai Yeen, James, et al.
Publicado: (2014)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
por: Salek, Sam, et al.
Publicado: (2019)

Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level
por: Calabrò, G. E., et al.
Publicado: (2018)

Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International Experience
por: Gałązka-Sobotka, Małgorzata, et al.
Publicado: (2021)

Evaluation of the Performance of the Turkish Regulatory Agency: Recommendations for Improved Patients’ Access to Medicines
por: Koyuncu, Oguzhan, et al.
Publicado: (2020)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations
por: Hoxhaj, Ilda, et al.
Publicado: (2022)

Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients’ Access to Medicines
por: Keyter, Andrea, et al.
Publicado: (2019)

Evaluation of the effectiveness and efficiency of the East African community joint assessment procedure by pharmaceutical companies: Opportunities for improvement
por: Ngum, Nancy, et al.
Publicado: (2022)

Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations
por: Yuba, Tania Yuka, et al.
Publicado: (2018)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

Reimbursed Medication Adherence Enhancing Interventions in European Countries: Results of the EUREcA Study
por: Ágh, Tamás, et al.
Publicado: (2022)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

Stratified Medicine and Reimbursement Issues
por: Fugel, Hans-Joerg, et al.
Publicado: (2012)

Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges
por: Kardas, Przemysław, et al.
Publicado: (2022)

Real-world evidence (RWE): A challenge for regulatory agencies discussion of the RWE conference with the network of the european medicine agencies, patients, and experts
por: Maison, Patrick, et al.
Publicado: (2022)

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2020)

The Utility of a Rapid Review Evaluation Process to a National HTA Agency
por: Varley, Áine, et al.
Publicado: (2021)

A practical approach to communicating benefit-risk decisions of medicines to stakeholders
por: Leong, James, et al.
Publicado: (2015)

The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making
por: Donelan, Ronan, et al.
Publicado: (2016)

Critical Appraisal of Reimbursement List in Bosnia and Herzegovina
por: Mujkic, Sabina, et al.
Publicado: (2017)

Critical Reflections on Reimbursement and Access of Advanced Therapies
por: Simoens, Steven, et al.
Publicado: (2022)

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
por: Tafuri, Giovanni, et al.
Publicado: (2016)

The South African Medicines Control Council: Comparison of Its Registration Process With Australia, Canada, Singapore, and Switzerland
por: Keyter, Andrea, et al.
Publicado: (2019)

The South African Regulatory System: Past, Present, and Future
por: Keyter, Andrea, et al.
Publicado: (2018)

Can Standardisation of the Public Assessment Report Improve Benefit-Risk Communication?
por: Keyter, Andrea, et al.
Publicado: (2020)

The Reliability and Relevance of a Quality of Decision Making Instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for Use During the Lifecycle of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2019)

Nutrition, a health technology that deserves increasing interest among HTA doers. A systematic review
por: Gutiérrez-Ibarluzea, Iñaki, et al.
Publicado: (2015)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective
por: Kisser, Agnes, et al.
Publicado: (2021)

HTA Implementation Roadmap in Central and Eastern European Countries
por: Kaló, Zoltán, et al.
Publicado: (2016)

The Turkish Medicines and Medical Devices Agency: Comparison of Its Registration Process with Australia, Canada, Saudi Arabia, and Singapore
por: Mashaki Ceyhan, Emel, et al.
Publicado: (2018)

Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature
por: Bujar, Magdalena, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vvtjsnv0b8l8qb44cc9f7n5ljl